Clinical relevance of soluble HLA-1 and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
Clinical relevance of soluble HLA-1 and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
复制标题
DOI：
10.1016/j.leukres.2006.02.013
复制
发表时间：
2007-02-01
影响因子：
2.7
通讯作者：
Giles, Francis J.
中科院分区：
文献类型：
--
作者：
Albitar, Maher;Vose, Julie M.;Giles, Francis J.
非霍奇金淋巴瘤(NHL)和霍奇金病(HD)患者的预后与血浆β2微球蛋白(β2M)水平呈负相关，β2微球蛋白是人类白细胞抗原I类分子的一个亚单位。我们检测了NHL和HD患者血清中可溶性人类白细胞抗原-I(sHLA-I)水平的临床相关性。对65例NHL患者和37例HD患者的血清进行了盲法分析。NHL和HD患者的sHL-I和β2M水平显著高于正常对照组。在非霍奇金淋巴瘤患者中，sHLA-I水平与临床行为的相关性类似于β2M。然而，结合β2M、sHLAI和国际预后指数的多因素分析显示，sHLAI水平升高(>；312.6µg/100mL)的NHL患者的生存期显著缩短，与国际预后指数评分和β2m无关。在HD患者中，β2M水平与临床行为相关，而与sHLA-I水平无关。这些发现不仅确立了sHLA-I作为一种独立的肿瘤标志物在NHL中的作用，可用于对患者进行分层，而且提示β2M和sHL-I可能反映了HD和NHL不同的生物学过程。需要进一步的研究来评估sHLA-I的免疫调节特性是否可能是它与作为HD临床行为指标的β2M不同的原因。(C)2006爱思唯尔有限公司。保留所有权利。
Plasma levels of beta-2 microglobulin (beta 2M), a subunit of the human leukocyte antigen-class I (HLA-I) molecule, correlate negatively with outcome in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive NHL (n = 65) and HD (n = 37) patients were analyzed in a blinded manner. NHL and HD patients had significantly higher levels of sHLA-I and beta 2M than control subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a fashion similar to that of beta 2M. However, multivariate analysis incorporating beta 2M, sHLA-I, and international prognostic index (IPI) indicated that NHL patients with elevated (> 312.6 mu g/100 mL) sHLA-I levels had significantly shorter survival, independent of IPI score as well as beta 2M. In HD patients, beta 2M but not sHLA-I levels were associated with clinical behavior. These findings not only establish the role of sHLA-I as an independent tumor marker in NHL that can be used to stratify patients, but also suggest that beta 2M and sHLA-I may reflect different biological processes in HD and NHL. Further studies are needed to assess whether the immumonodulatory properties of sHLA-I may be responsible for its divergence from beta 2M as an indicator of clinical behavior in HD. (c) 2006 Elsevier Ltd. All rights reserved.